Alzheimer Europe’s July-August2019 newsletter brings you the latest news on developments in the dementia field, across Europe and beyond.
Summaries of a few of our top stories appear below.
Our monthly newsletter has over 8,000 subscribers and we are always happy to receive their comments, or suggested news items to share in future issues.
On 28-29 June 2019, the leaders of the G20 met in Osaka, Japan, to address major global economic challenges. For the first time, dementia was specifically recognised as a global health priority in the declaration of the summit.
The draft strategic plan for Horizon Europe has shown brain research is being hugely undervalued. Together with 17 other organisations, we are calling for this to be rectified. Please support this campaign.
On 11 July, the pharmaceutical companies Novartis and Amgen announced the decision to discontinue two Phase II/III clinical trials in the Alzheimer's Prevention Initiative (API) Generation programme based on a planned analysis
The newly-elected European Parliament has voted to confirm the first female President of the European Commission, Ursula von der Leyen. Ms von der Leyen is the first ever female Commission President.
Alzheimer Europe continues to develop and improve its Clinical Trials Watch (CTW), an innovative online resource providing up-to-date accessible information on clinical trials currently recruiting participants in a least one European country.
This newsletter received funding under an operating grant from the European Union’s Health Programme (2014-2020).
The content of this newsletter represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.
Alzheimer Europe’s 
On 28-29 June 2019, the leaders of the G20 met in Osaka, Japan, to address major global economic challenges. For the first time, dementia was specifically recognised as a global health priority in the declaration of the summit.
The draft strategic plan for Horizon Europe has shown brain research is being hugely undervalued. Together with 17 other organisations, we are calling for this to be rectified. Please support this campaign.
On 11 July, the pharmaceutical companies Novartis and Amgen announced the decision to discontinue two Phase II/III clinical trials in the Alzheimer's Prevention Initiative (API) Generation programme based on a planned analysis
The newly-elected European Parliament has voted to confirm the first female President of the European Commission, Ursula von der Leyen. Ms von der Leyen is the first ever female Commission President.
Alzheimer Europe continues to develop and improve its Clinical Trials Watch (CTW), an innovative online resource providing up-to-date accessible information on clinical trials currently recruiting participants in a least one European country.
This newsletter received funding under an operating grant from the European Union’s Health Programme (2014-2020).